WO2022270972A1 - 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드 - Google Patents
심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드 Download PDFInfo
- Publication number
- WO2022270972A1 WO2022270972A1 PCT/KR2022/009027 KR2022009027W WO2022270972A1 WO 2022270972 A1 WO2022270972 A1 WO 2022270972A1 KR 2022009027 W KR2022009027 W KR 2022009027W WO 2022270972 A1 WO2022270972 A1 WO 2022270972A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- efpeglenatide
- pharmaceutical composition
- cardiovascular disease
- type
- Prior art date
Links
- OJQLGILETRTDGQ-IRXDYDNUSA-N (2s)-1-[3-[2-[3-[[(5s)-5-amino-5-carboxypentyl]amino]propoxy]ethoxy]propyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H](N)CCCCNCCCOCCOCCCN1CCC[C@H]1C(O)=O OJQLGILETRTDGQ-IRXDYDNUSA-N 0.000 title claims abstract description 136
- 229950004145 efpeglenatide Drugs 0.000 title claims abstract description 129
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 97
- 230000008085 renal dysfunction Effects 0.000 title claims abstract description 49
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 76
- 238000000034 method Methods 0.000 claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 55
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 43
- 208000017169 kidney disease Diseases 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims description 39
- 239000000902 placebo Substances 0.000 claims description 33
- 229940068196 placebo Drugs 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 31
- 230000034994 death Effects 0.000 claims description 26
- 231100000517 death Toxicity 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 24
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 238000011156 evaluation Methods 0.000 claims description 19
- 208000029078 coronary artery disease Diseases 0.000 claims description 16
- 230000009467 reduction Effects 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 229940109239 creatinine Drugs 0.000 claims description 12
- 206010002388 Angina unstable Diseases 0.000 claims description 10
- 208000007814 Unstable Angina Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 9
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 9
- 230000002411 adverse Effects 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 230000024924 glomerular filtration Effects 0.000 claims description 9
- 208000023516 stroke disease Diseases 0.000 claims description 9
- 239000003472 antidiabetic agent Substances 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 7
- 230000003293 cardioprotective effect Effects 0.000 claims description 7
- 230000035487 diastolic blood pressure Effects 0.000 claims description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 7
- 230000035488 systolic blood pressure Effects 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 229940127088 antihypertensive drug Drugs 0.000 claims description 6
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 6
- 229960003105 metformin Drugs 0.000 claims description 6
- 230000000391 smoking effect Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 102000003673 Symporters Human genes 0.000 claims description 4
- 108090000088 Symporters Proteins 0.000 claims description 4
- 229940127218 antiplatelet drug Drugs 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 4
- 230000002459 sustained effect Effects 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 3
- 239000000883 anti-obesity agent Substances 0.000 claims description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 229940125708 antidiabetic agent Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- 229940125710 antiobesity agent Drugs 0.000 claims description 3
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 13
- 230000003907 kidney function Effects 0.000 description 11
- 239000002131 composite material Substances 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000003442 weekly effect Effects 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 206010001580 Albuminuria Diseases 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 3
- 208000024330 bloating Diseases 0.000 description 3
- 230000007211 cardiovascular event Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 2
- 241000320892 Clerodendrum phlomidis Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 208000001288 gastroparesis Diseases 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002473 insulinotropic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000035485 pulse pressure Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001084 renoprotective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229940125365 angiotensin receptor blocker-neprilysin inhibitor Drugs 0.000 description 1
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000032289 susceptibility to 2 pancreatic cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- Efpeglenatide is an International Nonproprietary Name (INN) assigned by the WHO for a long-acting CA-exendin-4 derivative (LAPSCA-Exendin4).
- Efpeglenatide is a weekly subcutaneously injected GLP-1 RA that lowers glucose levels without causing hypoglycemia, and contains a modified exendin-4 molecule conjugated with an IgG4 Fc fragment (Patent Documents 1 and 2).
- CV endpoints cardiovascular endpoints
- UCR urine albumin to creatinine ratio
- renal dysfunction previous CV disease
- CV risk factors similar factors increase the incidence of height endpoints.
- diabetes is known to increase cardiovascular disease and deteriorate kidney function, but it is not well known whether the incidence of cardiovascular disease decreases when diabetes is controlled, and it is also known that kidney function is improved only in some substances.
- GLP-1 RAs glucagon-like peptide 1 receptor agonists
- Patent Document 1 WO 2008/082274 A1
- Patent Document 2 WO 2009/011544 A2
- the present inventors completed the present invention by confirming through clinical trials that cardiovascular disease was reduced and renal function was improved when diabetes was controlled using efpeglenatide. Therefore, the present disclosure provides the use of efpeglenatide as follows:
- Efpeglenatide is provided for preventing the occurrence of, reducing the risk of occurrence of, or delaying the progression of cardiovascular disease or renal dysfunction in a patient.
- a pharmaceutical composition comprising efpeglenatide, wherein the pharmaceutical composition prevents or reduces the risk of cardiovascular disease or renal dysfunction in a patient.
- a method for preventing or reducing the risk of cardiovascular disease or renal dysfunction in a type 2 diabetic patient comprising administering to the patient an effective amount of efpeglenatide.
- a method of treating type 2 diabetes comprising administering to a patient an effective amount of efpeglenatide, wherein the patient does not experience side effects related to cardiovascular disease or renal dysfunction during treatment. .
- efpeglenatide for use in the treatment of a patient with type 2 diabetes, wherein said efpeglenatide prevents or reduces the risk of developing cardiovascular disease or renal dysfunction in said patient. provide use.
- One aspect provides efpeglenatide for preventing the occurrence of, reducing the risk of occurrence of, or delaying the progression of cardiovascular disease or renal dysfunction in a patient.
- Another aspect provides a pharmaceutical composition comprising efpeglenatide, wherein the pharmaceutical composition prevents or reduces the risk of developing cardiovascular disease or renal dysfunction in a patient. .
- Another aspect provides a method for preventing or reducing the risk of developing cardiovascular disease or renal dysfunction in a patient with type 2 diabetes comprising administering to the patient an effective amount of efpeglenatide.
- Another aspect is a method of treating type 2 diabetes comprising administering to a patient an effective amount of efpeglenatide, wherein the patient does not experience side effects related to cardiovascular disease or renal dysfunction during treatment.
- Another aspect is the use of efpeglenatide for use in the treatment of a patient with type 2 diabetes, wherein said efpeglenatide prevents or reduces the risk of developing cardiovascular disease or renal dysfunction in said patient. That is, it provides a use.
- efpeglenatide is a type of insulinotropic peptide conjugate in which an exendin-4 derivative is linked to an immunoglobulin Fc region through a non-peptide polymer.
- Materials of such insulinotropic peptide conjugates e.g., efpeglenatide
- their medicinal uses are described in PCT International Publication Nos. WO 2008/082274 A1 and WO 2009/011544 A2, each of which is incorporated herein by reference. do.
- a patient with type 2 diabetes who (1) has a previous cardiovascular (CV) disease, or (2) has an eGFR between 25 and 59.9 ml/min/1.73 m 2 and meets one or more other CV risk factors. Participants were subcutaneously administered weekly efpeglenatide 4 mg or 6 mg, or placebo. As a result, compared to the placebo group, the efpeglenatide group showed a 27% reduction in major adverse CV events (MACE) and a 32% reduction in the composite kidney outcome, demonstrating cardiovascular protection and renal function. It was confirmed to have a statistically significant beneficial effect in protection.
- MACE major adverse CV events
- efpeglenatide can be used in uses, pharmaceutical compositions, methods, etc. for preventing the occurrence of, reducing the risk of occurrence of, or delaying the progression of cardiovascular disease or renal dysfunction in a patient.
- a patient herein refers to an individual in need of preventing the occurrence of, reducing the risk of occurrence of, or delaying the progression of cardiovascular disease or renal dysfunction.
- the patient may be a type 2 diabetes mellitus (T2DM) patient.
- T2DM type 2 diabetes mellitus
- the patient may be a non-alcoholic steatohepatitis (NASH) patient.
- NASH non-alcoholic steatohepatitis
- the patient may be a type 2 diabetic patient with HbA1c greater than 7%. If HbA1c is less than 5.7%, it is normal, and if HbA1c is more than 7%, type 2 diabetes can be diagnosed.
- the patient may be a patient with type 2 diabetes who has or is at risk of having cardiovascular disease, kidney disease, or both.
- the patient may be a type 2 diabetic patient with cardiovascular disease.
- the patient is an adult (eg, 18 years of age or older).
- the patient may be a type 2 diabetic patient aged 18 years or older with cardiovascular disease.
- the cardiovascular disease may be selected from coronary artery disease, stroke and peripheral arterial disease.
- the cardiovascular disease may be a previous cardiovascular disease or a current cardiovascular disease.
- the patient may be a type 2 diabetic patient aged 18 years or older with a cardiovascular disease selected from coronary artery disease, stroke, and peripheral arterial disease.
- the patient may be a type 2 diabetic patient having or at risk of having a cardiovascular disease.
- the patient may be a type 2 diabetic patient with renal disease.
- the renal disease may mean that renal function is impaired, and can be evaluated by eGFR.
- Estimated glomerular filtration rate (eGFR) can be calculated by the MDRD formula using age, sex, race, and serum creatinine concentration, and details of the MDRD formula refer to the Examples herein.
- eGFR can be used to evaluate renal function.
- eGFR is 60 or more to less than 90 ml / min / 1.73 m 2 , it is defined as renal impairment and mild GFR reduction, and if eGFR is 30 or more to less than 60 ml / min / 1.73 m 2 , it is defined as moderate GFR reduction , an eGFR greater than or equal to 15 and less than 30 ml/min/1.73 m 2 is defined as severe GFR reduction, and an eGFR less than 15 ml/min/1.73 m 2 or dialysis as renal failure.
- the patient may have a moderate or severe decrease in GFR.
- the patient may have an eGFR of 25 or more to less than 60 ml/min/1.73 m 2 .
- the patient's eGFR may be 25 to 59.9 ml/min/1.73 m 2 .
- the patient may have one or more cardiovascular disease risk factors.
- the patient may be defined as having or at risk of having a cardiovascular event.
- the cardiovascular disease risk factor may be selected from the following (a) to (f):
- BMI body mass index
- the patient may be a type 2 diabetic patient having an eGFR of 25 to 59.9 ml/min/1.73 m 2 and one or more cardiovascular disease risk factors defined above.
- the patient has an eGFR of 25 to 59.9 ml/min/1.73 m 2 , and may be a male aged 50 years or older or a female aged 55 years or older with type 2 diabetes having one or more cardiovascular disease risk factors defined above. there is.
- the patient may be a patient with type 2 diabetes who has or is at risk of having both kidney disease and cardiovascular disease.
- the patient has type 2 diabetes and (1) is 18 years of age or older with prior coronary artery disease, stroke, or peripheral arterial disease; Or (2) eGFR is 25 to 59.9 ml/min/1.73 m 2 and may be a male over 50 years of age or a female over 55 years of age who satisfies at least one of the cardiovascular disease risk factors (a) to (f) defined above. there is.
- the patient is not necessarily limited to type 2 diabetic patients, and may include any patient who has or is at risk of having cardiovascular disease and/or kidney disease.
- the patient may be a patient without any of gastroparesis, uncontrolled reflux, prolonged nausea or vomiting, severe retinal disease, and pancreatitis, but is not limited thereto.
- the patient may be a type 2 diabetic patient who has not used a glucagon-like peptide-1 (GLP-1) receptor agonist or a dipeptidyl peptidase-4 (DPP-4) inhibitor within the past 3 months.
- GLP-1 glucagon-like peptide-1
- DPP-4 dipeptidyl peptidase-4
- the efpeglenatide may be administered to a patient according to an appropriate administration route, dose, and usage in order to prevent, reduce the risk of, or delay the progression of cardiovascular disease or renal dysfunction in a patient. there is.
- the efpeglenatide can be administered to a patient by any suitable route of administration.
- the efpeglenatide may be administered subcutaneously.
- an appropriate method known in the art may be used.
- the subcutaneous administration may be performed by a syringe pre-filled with an appropriate dose of efpeglenatide, but is not limited thereto.
- the efpeglenatide can be administered to the patient in an effective amount.
- the effective amount may be a pharmacologically effective amount.
- the effective amount may mean an amount capable of exhibiting the intended therapeutic effect of efpegletanide.
- the effective amount of efpeglenatide can be administered weekly.
- the effective amount of efpeglenatide may be 4 mg or 6 mg once a week. Therefore, the efpeglenatide may be administered at 4 mg or 6 mg once a week.
- the efpeglenatide may be administered 2 mg once a week for 4 weeks and then 4 mg once a week.
- the efpeglenatide may be administered 2 mg once a week for 4 weeks, then 4 mg once a week for 4 weeks, and then 6 mg once a week.
- the efpeglenatide may be administered once a week for a period of at least 1 time, at least 4 weeks, at least 3 months, at least 6 months, or at least 1 year.
- the treatment period may be extended until the desired therapeutic effect can be achieved.
- the efpeglenatide is used to prevent the occurrence, reduce the risk of occurrence, or delay the progression of cardiovascular disease or renal dysfunction in a patient. It is provided for use.
- the "preventing occurrence of cardiovascular disease or renal dysfunction” may mean preventing new occurrence or aggravation of cardiovascular disease or renal dysfunction in a patient by administration of efpeglenatide.
- the "reducing the risk of cardiovascular disease or renal dysfunction” means that the risk of a new occurrence or aggravation of cardiovascular disease or renal dysfunction in a patient is reduced by administration of efpeglenatide compared to administration of placebo. can do.
- delaying the progression of cardiovascular disease or renal dysfunction means delaying the occurrence of a new cardiovascular disease or renal dysfunction in a patient by administration of efpeglenatide, or delaying the pre-existing cardiovascular disease or renal function It can mean reducing the rate at which a disorder progresses, or reducing the rate at which cardiovascular disease or renal dysfunction worsens.
- the efpeglenatide can be used to treat type 2 diabetes in patients at risk of developing cardiovascular disease or renal dysfunction.
- the use of efpeglenatide to treat patients with type 2 diabetes may reduce the patient's risk of developing cardiovascular disease or kidney dysfunction compared to placebo or other treatments for type 2 diabetes. Accordingly, the patient may not experience cardiovascular events (eg MACE) or renal events (eg side effects related to renal dysfunction) during treatment of a disease with efpeglenatide.
- cardiovascular events eg MACE
- renal events eg side effects related to renal dysfunction
- the efpeglenatide is used for preventing, reducing the risk of, or delaying the progression of cardiovascular disease or renal dysfunction in a subject in need of treatment by administration of efpeglenatide can be provided as That is, the efpeglenatide may be provided for cardiovascular or renal protection.
- the subject in need of treatment by the administration of efpeglenatide may be a patient with type 2 diabetes or may not be a patient with type 2 diabetes. If not a patient with type 2 diabetes, the subject may be a patient with a disease that can be treated by administration of efpeglenatide.
- the cardiovascular disease or renal dysfunction can be determined by whether or not the patient has experienced an outcome.
- the cardiovascular disease may be a primary endpoint.
- the cardiovascular disease may be a major adverse CV event (MACE).
- MACE is a term widely known in the art and may be selected from non-fatal myocardial infarction, non-fatal stroke, and death from cardiovascular or unknown causes.
- the efpeglenatide can reduce the risk of developing MACE by at least 20%, for example by 27%, compared to placebo.
- the efpeglenatide administration group may have a MACE incidence of 3.9 per 100 per year, whereas the placebo group may have a MACE incidence of 5.3 per 100 per year.
- the renal dysfunction may be a secondary endpoint.
- the renal dysfunction may be a composite kidney outcome.
- the renal dysfunction may include one or more renal complex evaluation indicators selected from the following (a) to (d):
- macroalbuminuria defined as UACR greater than 33.9 mg/mmol and greater than or equal to 30% above baseline
- baseline means a value measured for each individual patient before administration of efpeglenatide. Therefore, the reference value may be different for each individual patient.
- the efpeglenatide can reduce the risk of developing the above-defined renal complex evaluation index by 30% or more, for example, 32%, compared to placebo. Specifically, the efpeglenatide can prevent, reduce the risk of, or delay the progression of macroalbuminuria in patients. The efpeglenatide can prevent, reduce the risk of, or delay the progression of eGFR so that it does not decrease by 40% or more continuously for 30 days or longer in the patient. The efpeglenatide may reduce the risk of renal dialysis in patients. The efpeglenatide can prevent, reduce the risk of, or delay the progression of eGFR to less than 15 ml/min/1.73 m 2 continuously for more than 30 days in a patient.
- the cardiovascular disease or renal dysfunction may be other endpoints.
- the cardiovascular disease may include hospitalization due to MACE, coronary recanalization and unstable angina.
- the efpeglenatide can prevent the occurrence, reduce the risk of occurrence, or delay the progression of cardiovascular diseases selected from MACE, coronary recanalization and hospitalization for unstable angina.
- the efpeglenatide may reduce the risk of developing death or non-cardiovascular death due to MACE as compared to placebo.
- the efpeglenatide may be administered in combination with any one or more other therapeutic substances. Even when the efpeglenatide is used in combination with other therapeutic substances, it can exert an effect of preventing, reducing the risk of, or delaying the progression of cardiovascular disease or renal dysfunction in a patient.
- the other therapeutic substance may be selected from hypoglycemic drugs, cardioprotective drugs, antidiabetic agents, antiobesity agents, antihyperlipidemic agents, antiatherosclerotic agents, antihypertensive agents, antiplatelet agents, antithrombotic agents and anticoagulants, but is not limited thereto.
- the other therapeutic substance is not particularly limited as long as it is known in the art, but it is preferable to use a substance that does not significantly affect the efficacy of efpeglenatide.
- the other therapeutic substance may be selected from a sodium glucose co-transporter 2 (SGLT2) inhibitor and metformin.
- SGLT2 sodium glucose co-transporter 2
- metformin a sodium glucose co-transporter 2
- the other therapeutic agent may be an SGLT2 inhibitor.
- the other therapeutic agent may be administered concurrently, sequentially, or separately with efpeglenatide.
- the dosage and route of administration of the other therapeutic substance may be selected appropriate for the substance.
- the pharmaceutical composition according to one aspect includes efpeglenatide, and may be for preventing or reducing the risk of cardiovascular disease or renal dysfunction in a patient.
- the pharmaceutical composition may be for preventing, treating or improving cardiovascular disease or renal dysfunction.
- the pharmaceutical composition may be for treating type 2 diabetes.
- the pharmaceutical composition may be used to prevent, reduce the risk of, or delay the progression of cardiovascular disease or renal dysfunction in type 2 diabetic patients.
- the pharmaceutical composition may be for protecting the cardiovascular or renal in type 2 diabetic patients.
- the efpeglenatide may be in any pharmaceutically acceptable form.
- pharmaceutically acceptable refers to an amount sufficient to exhibit a therapeutic effect and not causing side effects, and the type of disease, age, weight, health, sex of the patient, sensitivity to the drug of the patient, and route of administration. , It can be easily determined by a person skilled in the art according to factors well known in the medical field, such as an administration method, the number of administrations, a treatment period, combination or drugs used simultaneously.
- the pharmaceutical composition may be formulated in a form suitable for administering efpeglenatide to a patient.
- the pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient or diluent. Suitable carriers, excipients and diluents for formulation can be appropriately selected by those skilled in the art from any known materials.
- the pharmaceutical composition may include a pharmaceutically effective amount of efpeglenatide and an excipient.
- the pharmaceutical composition may be a liquid formulation.
- liquid formulations of efpeglenatide see, for example and without limitation, WO 2014/017845, incorporated herein by reference.
- the pharmaceutical composition may be an injection.
- the pharmaceutical composition may be an injection for subcutaneous administration.
- the pharmaceutical composition may be used by mixing arbitrary ingredients selected from buffers, stabilizers, tonicity agents, preservatives, solubilizers, and the like.
- a method for preventing or reducing the risk of developing cardiovascular disease or renal dysfunction in a patient with type 2 diabetes comprising administering to the patient an effective amount of efpeglenatide. .
- a method of treating type 2 diabetes comprising administering to a patient an effective amount of efpeglenatide, wherein the patient does not experience side effects related to cardiovascular disease or renal dysfunction during treatment method is provided.
- a method for cardiovascular or renal protection during treatment of type 2 diabetes comprising administering to a patient an effective amount of efpeglenatide is provided.
- the step of identifying the patient may be further included.
- the patient is an individual in need of administration of efpeglenatide, an individual in need of reducing the risk of cardiovascular disease or renal dysfunction by administering efpeglenatide, or an individual suitable for treatment with efpeglenatide.
- the patient may be a patient with type 2 diabetes who has or is at risk of having cardiovascular disease, kidney disease, or both.
- the step of identifying the patient with any one of the following may be further included:
- Type 2 diabetic patients with coronary artery disease, stroke or peripheral arterial disease (1) Type 2 diabetic patients with coronary artery disease, stroke or peripheral arterial disease; or
- BMI body mass index
- efpeglenatide for use in the treatment of a patient with type 2 diabetes, wherein said efpeglenatide prevents or reduces the risk of developing cardiovascular disease or renal dysfunction in said patient. It provides a use, which is to reduce.
- efpeglenatide for cardiovascular or renal protection during treatment of a patient with type 2 diabetes.
- Redundant content is omitted in consideration of the complexity of the present specification, and terms not otherwise defined in the present specification have meanings commonly used in the technical field to which the present invention belongs.
- Efpeglenatide may reduce the risk of developing a cardiovascular or renal event.
- efpeglenatide can be used for cardiovascular or renal protection in patients with type 2 diabetes who have or are at risk of having cardiovascular or renal disease.
- efpeglenatide can achieve the above effect even when used in combination with other drugs such as SGLT2 inhibitors.
- 1 to 4 are graphs of major cardiovascular and renal evaluation indexes.
- Figure 1 shows the cumulative risk of the primary evaluation index MACE.
- Figure 2 shows the cumulative risk of three prespecified secondary endpoints (MACE, coronary revascularization or hospitalization for unstable angina).
- MACE prespecified secondary endpoints
- Figure 3 shows the cumulative risk of the second renal complex evaluation index.
- the renal complex evaluation index was macroalbuminuria; >40% reduction in eGFR over 30 days; renal dialysis for more than 90 days; or an eGFR of less than 15 ml/min/1.73 m 2 for more than 30 days.
- Figure 4 shows the cumulative risk of secondary endpoint MACE or non-CV death.
- Efpeglenatide is a weekly subcutaneously injected GLP-1 RA that lowers glucose levels without causing hypoglycemia, and contains a modified exendin-4 molecule conjugated to an IgG4 Fc fragment. It is well tolerated and has the same mechanism of action as the human GLP-1-based GLP-1 RA, which reduces CV endpoints, so that efpeglenatide has CV and renal benefits in diabetic patients with CV and/or renal disease. was hypothesized, and this hypothesis was tested in a clinical trial.
- This clinical trial is an international randomized controlled trial conducted at 344 sites in 28 countries. Participants were selected from those with Type 2 diabetes mellitus (T2DM) and HbA1c >7%: (1) 18 years of age or older with prior coronary artery disease, stroke, or peripheral arterial disease; or (2) males aged 50 years or older who have an estimated glomerular filtration rate (eGFR) of 25 to 59.9 ml/min/1.73 m 2 and satisfy one or more of the following cardiovascular disease risk factors (a) to (f) or women aged 55 years or older:
- T2DM Type 2 diabetes mellitus
- HbA1c >7%: (1) 18 years of age or older with prior coronary artery disease, stroke, or peripheral arterial disease; or (2) males aged 50 years or older who have an estimated glomerular filtration rate (eGFR) of 25 to 59.9 ml/min/1.73 m 2 and satisfy one or more of the following cardiovascular disease risk factors (a) to (f) or women aged 55 years or older:
- BMI body mass index
- the main exclusion criteria were gastroparesis, uncontrolled reflux, prolonged nausea or vomiting, severe retinal disease, pancreatitis, or use of a GLP-1 receptor agonist or DPP-4 inhibitor within the past 3 months.
- Eligible participants were randomly assigned to receive 4 mg efpeglenatide, 6 mg efpeglenatide, or placebo in a 1:1:1 ratio.
- the route of administration was self-administered subcutaneously, and the dose and frequency of administration were as follows:
- Study drug was provided in prefilled syringes that were masked and appeared identical. Randomization was performed using an interactive web response system (IWRS) stratified by the use of sodium glucose co-transporter 2 (SGLT2) inhibitors to minimize differences between groups in regimen with these cardioprotective drugs. . Only the Data Monitoring Committee (DMC) had access to unmasked data until the database was locked.
- IWRS interactive web response system
- SGLT2 sodium glucose co-transporter 2
- Study drug was added to the on-going regimen prior to randomization. If baseline HbA1c is less than 7.5%, investigators may reduce any insulin, sulfonylurea, or meglitinide dose to minimize hypoglycemia. Thereafter, hypoglycemic drugs were kept unchanged for the first 12 weeks, after which all drugs except GLP-1 RA or DPP-4 inhibitors could be added. Post-randomization visits occurred at Weeks 12, 24, and every 24 weeks with interim phone visits. Those who missed up to 2 doses of study drug were encouraged to resume their usual dose unless contraindication existed. If more than three consecutive doses were missed, a two-sided masked titration was restarted.
- MACE major adverse CV event
- the secondary outcome is an expanded MACE (including hospitalization for coronary artery recanalization or unstable angina other than MACE), and a composite kidney outcome including the following (a) to (d) ) includes:
- macroalbuminuria ie, urine albumin-to-creatinine ratio (UACR) greater than 300 mg/g or 33.9 mg/mmol and UACR greater than or equal to 30% above baseline
- Exploratory endpoints included components of the extended MACE and height assessment index, death from any cause, hospitalization for heart failure, HbA1c, vital signs, body weight, anti-eppeglenatide antibodies, pancreatic enzymes, and other laboratory tests.
- renal function index defined as >40% reduction in eGFR for >30 days, or end-stage renal disease (dialysis >90 days, kidney transplant, or eGFR ⁇ 15 ml/min/1.73 m ⁇ 2 >>30days); or death of any cause; or
- Sample size was calculated using PASS 13 software (NCSS, LLC, Kaysville, UT), reduction analysis was performed using the “bayesmeta” package in R version 3.5.1 (R Foundation for Statistical Computing), and all other statistical Analysis was performed using SAS version 9.4.
- a randomized controlled trial conducted at 344 locations in 28 countries was conducted in patients with type 2 diabetes who (1) had a previous CV disease or (2) had an eGFR between 25 and 59.9 ml/min/1.73 m 2 and at least one other CV risk. People who satisfied the factors were recruited. Participants were randomly assigned to receive subcutaneous weekly efpeglenatide 4 mg or 6 mg, or placebo, stratified according to whether or not they used an SGLT2 inhibitor. The primary endpoint was first MACE, defined as nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or unknown causes.
- MACE defined as nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular or unknown causes.
- the first event determined is shown in Table 2.
- 1 to 4 are graphs of major cardiovascular and renal evaluation indexes.
- Non-inferiority P values are for hazard ratios less than or equal to 1.8 and less than or equal to 1.3; MACE: major cardiovascular event defined as nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular (CV) causes; 1 MACE or hospitalization for coronary recanalization or unstable angina; 2 Development of macroalbuminuria (defined as urinary albumin:creatinine greater than 33.9 mg/mmol and greater than or equal to 30% increase from baseline,
- the renal endpoint (decreased height or macroalbuminuria) was affected in 353 (13.0%) participants in the efpeglenatide group and 250 (18.4%) participants in the placebo group (HR 0.68, 95% CI 0.57, 0.79 ;P ⁇ 0.0001). Diarrhea, constipation, nausea, vomiting or bloating were more frequent in the efpeglenatide group.
- Efpeglenatide significantly improved several risk factors for both CV and kidney disease, including HbA1c, blood pressure, body mass index, LDL cholesterol, eGFR and albuminuria.
- HbA1c high risk factors for both CV and kidney disease
- body mass index low-density lipoprotein
- LDL cholesterol low-density lipoprotein
- eGFR low-density lipoprotein
- albuminuria a meta-regression Analysis suggested a linear relationship between the degree of lowering of HbA1c using GLP-1 RA and the risk of developing MACE.
- efpeglenatide may also have beneficial endothelial and microvascular effects.
- Other possible mechanisms include anti-inflammatory, anti-fibrotic, anti-atherogenic and vasodilatory and other hemodynamic effects, as noted in other GLP-1 RA studies.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
특징 | 두 그룹 |
에페글레나타이드 투여군
(4/6 mg) |
위약군 (Placebo) | |
수(N) | 4076 | 2717 | 1359 | |
연령(년) | 64.5 (8.2) | 64.6 (8.2) | 64.4 (8.3) | |
여성 | 1344 (33.0) | 925 (34.0) | 419 (30.8) | |
지역: | 캐나다/US | 1079 (26.5) | 728 (26.8) | 351 (25.8) |
멕시코/남아메리카 | 924 (22.7) | 605 (22.3) | 319 (23.5) | |
유럽 | 1285 (31.5) | 862 (31.7) | 423 (31.1) | |
기타 | 788 (19.3) | 522 (19.2) | 266 (19.6) | |
백인 혈통 | 3534 (86.7) | 2372 (87.3) | 1162 (85.5) | |
당뇨병 지속기간 | 15.4 (8.8) | 15.6 (8.8) | 15.1 (8.7) | |
현재 흡연자 | 633 (15.5) | 427 (15.7) | 206 (15.2) | |
이전 심혈관 질환(CVD)a | 3650 (89.6) | 2420 (89.1) | 1230 (90.5) | |
eGFR <60 ml/min/1.73m2b | 1287 (31.6) | 863 (31.8) | 424 (31.2) | |
이전 CVD & eGFR <60 ml/min/1.73m2 | 888 (21.8) | 585 (21.5) | 303 (22.3) | |
이전 심부전 | 737 (18.1) | 487 (17.9) | 250 (18.4) | |
이전 고혈압 | 3722 (91.3) | 2484 (91.4) | 1238 (91.1) | |
이전 당뇨망막병증c | 1342 (32.9) | 912 (33.6) | 430 (31.6) | |
N 알부민뇨 (%)d | 1977 (48.5) | 1319 (48.5) | 658 (48.4) | |
체질량지수 (kg/m2) | 32.7 (6.2) | 32.9 (6.2) | 32.4 (6.0) | |
심박수 (beats/min) | 72.8 (10.6) | 72.8 (10.6) | 72.8 (10.7) | |
수축기 BP | 134.9 (15.5) | 135.1 (15.5) | 134.4 (15.6) | |
이완기 BP | 76.7 (9.7) | 76.8 (9.7) | 76.6 (9.8) | |
HbA1c (%) | 8.91 (1.48) | 8.90 (1.46) | 8.94 (1.52) | |
eGFR (ml/min/1.73m2)b | 72.4 (22.4) | 72.2 (21.9) | 72.9 (23.3) | |
중앙값 알부민/크레아틴 (mg/mmol) |
3.2 (1.1 - 12.9) |
3.2 (1.0 - 13.5) |
3.2 (1.1 - 12.0) |
|
콜레스테롤 (mmol/L) | 4.21 (1.23) | 4.21 (1.24) | 4.21 (1.22) | |
LDL 콜레스테롤 (mmol/L) | 2.07 (0.98) | 2.07 (0.98) | 2.08 (0.97) | |
HDL 콜레스테롤 (mmol/L) | 1.11 (0.31) | 1.12 (0.31) | 1.10 (0.31) | |
중앙 트리글리세리드 (mmol/L) | 1.91 (1.37 - 2.75) |
1.90 (1.36 - 2.74) |
1.93 (1.40 - 2.75) |
|
모든 종류의 인슐린 | 2560 (62.8) | 1720 (63.3) | 840 (61.8) | |
메트포르민 | 2985 (73.2) | 1993 (73.4) | 992 (73.0) | |
설포닐우레아 | 1036 (25.4) | 695 (25.6) | 341 (25.1) | |
SGLT2 억제제 | 618 (15.2) | 412 (15.2) | 206 (15.2) | |
혈당강하 약물 없음 | 85 (2.1) | 57 (2.1) | 28 (2.1) | |
ACE-I 또는 ARB 또는 ARNi | 3262 (80.0) | 2177 (80.1) | 1085 (79.8) | |
베타차단제(Beta Blocker) | 2670 (65.5) | 1795 (66.1) | 875 (64.4) | |
스타틴(Statin) | 3294 (80.8) | 2202 (81.1) | 1092 (80.4) | |
피브레이트(Fibrate) | 350 (8.6) | 233 (8.6) | 117 (8.6) | |
아세틸살리실산 | 2768 (67.9) | 1855 (68.3) | 913 (67.2) | |
기타 항혈소판제 | 1049 (25.7) | 705 (26.0) | 344 (25.3) | |
eGFR: 추정 사구체 여과율(estimated glomerular filtration rate); ACE-I: 안지오텐신 변환효소 억제제(angiotensin converting enzyme inhibitor); ARB: 안지오텐신 수용체 차단제(angiotensin receptor blocker); ARNI: 안지오텐신 수용체-네프릴리신 억제제(Angiotensin Receptor-neprilysin inhibitor); SGLT2: 나트륨-포도당 공동수송체 2(sodium-glucose co-transporter 2); 평균 (SD), 중앙값 (IQR) 또는 N (%)로 나타냄; a 관상동맥질환 (즉, 이전 심근경색, 왼쪽 대동맥 또는 2개 이상의 다른 관상동맥에서 50% 이상의 협착, 2개 이상의 관상동맥 또는 1개의 관상동맥에서 50% 이상의 협착이 있는 혈관재형성, 또는 허혈을 입증하는 비침습 검사 또는 이전 12개월 동안 불안정한 협심증 입원과 함께 1개 관상동맥에서 50% 이상의 협착); 뇌졸중, 또는 말초 동맥 질환(즉, 사지 혈관성형술, 말초동백 스텐팅 또는 우회, 순환 부전으로 인한 사지 또는 발 절단, 발목-팔 지수가 0.9 미만 또는 혈관조영 증거); b 4개 가변 MDRD 공식에 의한 eGFR: 175 x [혈청 크레아티닌 (μmol/L)/88.4]-1.154 x 연령 (년)-0.203 x 1.212 (흑인인 경우) x 0.742 (여성인 경우); c 자가보고 또는 유리체절제술, 레이저 요법 또는 안구 주사; d 알부민/크레아티닌 ≥ 30 mg/g 또는 3.39 mg/mmol |
에페글레나타이드 투여군
(4/6 mg) |
위약군 | HR (95%CI) | P | P | |||
N (%) | N/100 py | N (%) | N/100 py | (우월성) | (비열등성) | ||
1차 평가지표 (MACE) |
189 (7.0) | 3.9 | 125 (9.2) | 5.3 | 0.73 (0.58, 0.92) | 0.0069 | <0.0001 |
확장된 MACE1 | 257 (9.5) | 5.4 | 158 (11.6) | 6.8 | 0.79 (0.65, 0.96) | 0.020 | |
신장복합평가지표2 | 353 (13.0) | 7.7 | 250 (18.4) | 11.6 | 0.68 (0.57, 0.79) | <0.0001 | |
MACE 또는 비-CV 사망 | 216 (7.9) | 4.5 | 143 (10.5) | 6.0 | 0.73 (0.59, 0.91) | 0.0040 | |
신장 기능 평가지표3 | 121 (4.5) | 2.5 | 76 (5.6) | 3.1 | 0.77 (0.57, 1.02) | 0.072 | |
MACE, 비-CV 사망, HF, 또는 신장 기능 평가지표 | 243 (8.9) | 5.1 | 164 (12.1) | 7.0 | 0.71 (0.59, 0.87) | ||
심근경색 | 91 (3.3) | 1.9 | 58 (4.3) | 2.4 | 0.75 (0.54, 1.05) | ||
비치명적 심근경색 | 85 (3.1) | 1.7 | 53 (3.9) | 2.2 | 0.78 (0.55, 1.10) | ||
뇌졸중 | 47 (1.7) | 1.0 | 31 (2.3) | 1.3 | 0.74 (0.47, 1.17) | ||
비치명적 뇌졸중 | 41 (1.5) | 0.8 | 25 (1.8) | 1.0 | 0.80 (0.48, 1.31) | ||
CV로 인한 사망 | 75 (2.8) | 1.5 | 50 (3.7) | 2.1 | 0.72 (0.50. 1.03) | ||
총 사망 | 111 (4.1) | 2.2 | 69 (5.1) | 2.8 | 0.78 (0.58, 1.06) | ||
관상동맥재개통 | 126 (4.6) | 2.6 | 66 (4.9) | 2.8 | 0.93 (0.69. 1.26) | ||
불안정한 협심증 | 6 (0.2) | 0.1 | 4 (0.3) | 0.2 | 0.55 (0.13, 2.35) | ||
신규 거대알부민뇨 | 348 (12.8) | 7.6 | 244 (18.0) | 11.3 | 0.68 (0.58, 0.80) | ||
심부전 | 40 (1.5) | 0.8 | 31 (2.3) | 1.3 | 0.61 (0.38, 0.98) | ||
비열등성 P 값은 위험비 1.8 이하 및 1.3 이하에 대한 것임; MACE: 비치명적 심근경색, 비치명적 뇌졸중, 또는 심혈관(CV) 원인으로부터의 사망으로 정의된 주요 심혈관질환 사건; 1 MACE 또는 관상동맥재개통 또는 불안정 협심증으로 인한 입원; 2 거대알부민뇨 발생(소변 알부민:크레아티닌이 33.9 mg/mmol 초과 및 기준치보다 30% 이상 증가, 30일 이상 eGFR이 40% 이상 감소로 정의됨), 90일 이상 신장투석, 또는 30일 이상 eGFR가 15 ml/min/1.73 m²미만); 3 신장복합평가지표(알부민뇨 기준은 제외함) 또는 모든 원인의 사망의 복합 |
에페글레나타이드 투여군 | 위약군 | P | |
N (%) | N (%) | ||
이상반응으로 인한 중단 | 147 (5.4) | 49 (3.6) | 0.015 |
심각한 위장 사건 | 90 (3.3) | 25 (1.8) | 0.0090 |
변비, 설사, 메스꺼움, 구토 또는 팽만감 | 32 (1.2) | 6 (0.4) | 0.028 |
기타 심각한 위장 사건 | 59 (2.2) | 19 (1.4) | 0.10 |
확인된 췌장 사건 | 32 (1.2) | 15 (1.1) | 0.87 |
확인된 췌장암 | 2 (<0.1) | 3 (0.2) | N/A |
확인된 췌장염 | 11 (0.4) | 7 (0.5) | 0.59 |
모든 종류의 암 | 72 (2.6) | 37 (2.7) | 0.81 |
칼시토닌 상승 > 5.9 pM (20 pg/ml) | 41 (1.5) | 20 (1.5) | 0.99 |
갑상선 C-세포 신생물 | 0 | 0 | N/A |
심각한 저혈당증 | 24 (0.9) | 13 (1.0) | 0.67 |
당뇨망막병증 및 관련 합병증 | 47 (1.7) | 27 (2.0) | 0.50 |
급성 신부전 | 88 (3.2) | 39 (2.9) | 0.62 |
심각한 주사 부위 반응 | 0 | 1 (<0.1) | N/A |
심각한 알레르기 반응 | 5 (0.2) | 1 (<0.1) | N/A |
심각한 면역 복합 질환 | 13 (0.5) | 1 (<0.1) | 0.096 |
에페글레나타이드 투여군 데이터는 4 mg 및 6 mg 용량 투여군 모두를 결합한 것임; P값은 에페글레나타이드에 대한 무작위 할당과 지역 및 무작위화 계층에 대해 조정된 각 이상반응 간의 관계에 대한 Cox 모델로부터의 값임. |
Claims (61)
- 약학적 유효량의 에페글레나타이드(efpeglenatide) 및 부형제를 포함하는 약학적 조성물로서,상기 약학적 조성물은 환자에서 심혈관 질환 또는 신장 기능장애의 발생을 예방하거나, 이의 발생의 위험을 감소시키는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 환자는 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 환자는 비알코올성 지방간염(non-alcoholic steatohepatitis, NASH) 환자인 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 환자는 HbA1c가 7% 초과인 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 환자는 심혈관 질환, 신장 질환, 또는 이 두 질환 모두를 갖거나 가질 위험이 있는 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 환자는 심혈관 질환을 동반한 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 6에 있어서, 상기 환자는 18세 이상의 심혈관 질환을 동반한 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 6에 있어서, 상기 심혈관 질환은 관상동맥질환, 뇌졸중 및 말초동맥질환으로부터 선택되는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 환자는 신장 질환을 동반한 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 9에 있어서, 상기 환자는 추정 사구체 여과율(estimated glomerular filtration rate, eGFR)이 25 내지 59.9 ml/min/1.73 m2인 것인, 약학적 조성물.
- 청구항 9에 있어서, 상기 환자는 하나 이상의 심혈관 질환 위험인자를 갖는 것인, 약학적 조성물.
- 청구항 9에 있어서, 상기 환자는 하기 (a) 내지 (f)로부터 선택된 하나 이상의 심혈관 질환 위험인자를 갖는 것인, 약학적 조성물:(a) BMI(body mass index) 35 kg/m2 이상;(b) 스타틴계 약물 복용 중 직전 6개월 이내 LDL 3.36 mmol/L 초과이고, 남성의 경우 HDL 1.03 mmol/L 미만 또는 여성의 경우 HDL 1.29 mmol/L 미만;(c) 흡연;(d) UACR(urine albumin-to-creatinine ratio) 3 mg/mmol 이상;(e) 수축기 혈압 140 mmHg 이상 및 이완기 혈압 90 mmHg 이상이고, 혈압강하제 약물 복용 중; 및(f) 남성의 경우 55세 미만 또는 여성의 경우 65세 미만의 초기 관상동맥질환.
- 청구항 1에 있어서, 상기 환자는 추정 사구체 여과율(estimated glomerular filtration rate, eGFR)이 25 내지 59.9 ml/min/1.73 m2이고, 청구항 12에서 정의된 하나 이상의 심혈관 질환 위험인자를 갖는 50세 이상의 남성 또는 55세 이상의 여성 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 환자는 지난 3개월 이내에 GLP-1(Glucagon-like peptide-1) 수용체 작용제 또는 DPP-4(Dipeptidyl peptidase-4) 억제제를 사용하지 않은 제2형 당뇨병 환자인 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 에페글레나타이드는 피하 투여하는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 에페글레나타이드는 주 1회 4 mg 또는 6 mg 투여하는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 에페글레나타이드는 4주 동안 주 1회 2 mg 투여 후, 주 1회 4 mg 투여하는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 에페글레나타이드는 4주 동안 주 1회 2 mg 투여 후, 그 다음 4주 동안 주 1회 4 mg 투여 후, 주 1회 6 mg 투여하는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 약학적 조성물은 심혈관 질환 또는 신장 기능장애 발생의 위험이 있는 환자에서 제2형 당뇨병을 치료하기 위한 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 심혈관 질환은 주요 심혈관질환 사건(major adverse CV event, MACE)인 것인, 약학적 조성물.
- 청구항 20에 있어서, 상기 MACE는 비치명적 심근경색, 비치명적 뇌졸중, 및 심혈관 또는 분명하지 않은 원인으로부터의 사망으로부터 선택되는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 약학적 조성물은 위약에 비해 MACE 발생 위험을 20% 이상 감소시키는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 신장 기능장애는 하기 (a) 내지 (d)로부터 선택된 하나 이상의 신장복합평가지표를 포함하는 것인, 약학적 조성물:(a) 거대알부민뇨;(b) 30일 이상 지속적으로 eGFR이 40% 이상 감소;(c) 90일 이상 신장투석; 및(d) 30일 이상 지속적으로 eGFR이 15ml/min/1.73 m2 미만.
- 청구항 1에 있어서, 상기 거대알부민뇨는 UACR이 33.9 mg/mmol 초과이면서 기준치보다 30% 이상인 것으로 정의되는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 약학적 조성물은 위약에 비해 청구항 23에서 정의된 신장복합평가지표의 발생 위험을 30% 이상 감소시키는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 심혈관 질환은 MACE, 관상동맥재개통 및 불안정 협심증으로 인한 입원을 포함하는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 약학적 조성물은 위약에 비해 MACE로 인한 사망 또는 비-심혈관 사망의 발생 위험을 감소시키는 것인, 약학적 조성물.
- 청구항 1에 있어서, 상기 에페글레나타이드는 임의의 하나 이상의 다른 치료 물질과 병용하여 투여하는 것인, 약학적 조성물.
- 청구항 28에 있어서, 상기 다른 치료 물질은 혈당강하 약물, 심장보호 약물, 항당뇨병제, 항비만제, 항고지혈증제, 항죽상동맥경화제, 항고혈압제, 항혈소판제, 항혈전제 및 항응고제로부터 선택되는 것인, 약학적 조성물.
- 청구항 28에 있어서, 상기 다른 치료 물질은 SGLT2(sodium glucose co-transporter 2) 억제제 및 메트포르민 중에서 선택되는 것인, 약학적 조성물.
- 유효량의 에페글레나타이드를 환자에게 투여하는 단계를 포함하는, 제2형 당뇨병 환자에서 심혈관 질환 또는 신장 기능장애의 발생을 예방하거나, 이의 발생의 위험을 감소시키는 방법.
- 유효량의 에페글레나타이드를 환자에게 투여하는 단계를 포함하는, 제2형 당뇨병을 치료하는 방법으로서,상기 환자는 치료 중에 심혈관 질환 또는 신장 기능장애와 관련된 부작용을 경험하지 않는 것인 방법.
- 청구항 31 또는 32에 있어서, 상기 환자는 HbA1c가 7% 초과인 제2형 당뇨병 환자인 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 환자는 심혈관 질환, 신장 질환, 또는 이 두 질환 모두를 갖거나 가질 위험이 있는 제2형 당뇨병 환자인 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 환자는 심혈관 질환을 동반한 제2형 당뇨병 환자인 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 환자는 18세 이상의 심혈관 질환을 동반한 제2형 당뇨병 환자인 것인, 방법.
- 청구항 36에 있어서, 상기 심혈관 질환은 관상동맥질환, 뇌졸중 및 말초동맥질환으로부터 선택되는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 환자는 신장 질환을 동반한 제2형 당뇨병 환자인 것인, 방법.
- 청구항 38에 있어서, 상기 환자는 추정 사구체 여과율(estimated glomerular filtration rate, eGFR)이 25 내지 59.9 ml/min/1.73 m2인 것인, 방법.
- 청구항 38에 있어서, 상기 환자는 하나 이상의 심혈관 질환 위험인자를 갖는 것인, 방법.
- 청구항 38에 있어서, 상기 환자는 하기 (a) 내지 (f)로부터 선택된 하나 이상의 심혈관 질환 위험인자를 갖는 것인, 방법:(a) BMI(body mass index) 35 kg/m2 이상;(b) 스타틴계 약물 복용 중 직전 6개월 이내 LDL 3.36 mmol/L 초과이고, 남성의 경우 HDL 1.03 mmol/L 미만 또는 여성의 경우 HDL 1.29 mmol/L 미만;(c) 흡연;(d) UACR(urine albumin-to-creatinine ratio) 3 mg/mmol 이상;(e) 수축기 혈압 140 mmHg 이상 및 이완기 혈압 90 mmHg 이상이고, 혈압강하제 약물 복용 중; 및(f) 남성의 경우 55세 미만 또는 여성의 경우 65세 미만의 초기 관상동맥질환.
- 청구항 31 또는 32에 있어서, 상기 환자는 추정 사구체 여과율(estimated glomerular filtration rate, eGFR)이 25 내지 59.9 ml/min/1.73 m2이고, 청구항 12에서 정의된 하나 이상의 심혈관 질환 위험인자를 갖는 50세 이상의 남성 또는 55세 이상의 여성 제2형 당뇨병 환자인 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 환자는 지난 3개월 이내에 GLP-1(Glucagon-like peptide-1) 수용체 작용제 또는 DPP-4(Dipeptidyl peptidase-4) 억제제를 사용하지 않은 제2형 당뇨병 환자인 것인, 방법.
- 청구항 31 또는 32에 있어서, 에페글레나타이드의 투여 전에, 하기 중 어느 하나의 환자를 확인하는 단계를 더 포함하는 것인, 방법:(1) 관상동맥질환, 뇌졸중 또는 말초동맥질환을 가진 제2 당뇨병 환자; 또는(2) eGFR이 25 내지 59.9 ml/min/1.73 m2이고 하기 심혈관 질환 위험인자 (a) 내지 (f) 중 1개 이상을 만족하는 제2 당뇨병 환자:(a) BMI(body mass index) 35 kg/m2 이상;(b) 스타틴계 약물 복용 중 직전 6개월 이내 LDL 3.36 mmol/L 초과이고, 남성의 경우 HDL 1.03 mmol/L 미만 또는 여성의 경우 HDL 1.29 mmol/L 미만;(c) 흡연;(d) UACR(urine albumin-to-creatinine ratio) 3 mg/mmol 이상;(e) 수축기 혈압 140 mmHg 이상 및 이완기 혈압 90 mmHg 이상이고, 혈압강하제 약물 복용 중; 및(f) 남성의 경우 55세 미만 또는 여성의 경우 65세 미만의 초기 관상동맥질환.
- 청구항 31 또는 32에 있어서, 상기 투여는 피하 투여인 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드의 유효량은 4 mg 또는 6 mg인 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드는 주 1회 4 mg 또는 6 mg 투여하는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드는 4주 동안 주 1회 2 mg 투여 후, 주 1회 4 mg 투여하는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드는 4주 동안 주 1회 2 mg 투여 후, 그 다음 4주 동안 주 1회 4 mg 투여 후, 주 1회 6 mg 투여하는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 심혈관 질환은 MACE인 것인, 방법.
- 청구항 50에 있어서, 상기 MACE는 비치명적 심근경색, 비치명적 뇌졸중, 및 심혈관 또는 분명하지 않은 원인으로부터의 사망으로부터 선택되는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드는 위약에 비해 MACE 발생 위험을 20% 이상 감소시키는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 신장 질환 또는 신장 기능장애와 관련된 부작용은 하기 (a) 내지 (d)로부터 선택된 하나 이상의 신장복합평가지표를 포함하는 것인, 방법:(a) 거대알부민뇨;(b) 30일 이상 지속적으로 eGFR이 40% 이상 감소;(c) 90일 이상 신장투석; 및(d) 30일 이상 지속적으로 eGFR이 15ml/min/1.73 m2 미만.
- 청구항 53에 있어서, 상기 거대알부민뇨는 UACR이 33.9 mg/mmol 초과이면서 기준치보다 30% 이상인 것으로 정의되는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드는 위약에 비해 청구항 53에서 정의된 신장복합평가지표의 발생 위험을 30% 이상 감소시키는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 심혈관 질환은 MACE, 관상동맥재개통 및 불안정 협심증으로 인한 입원을 포함하는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드는 위약에 비해 MACE로 인한 사망 또는 비-심혈관 사망의 발생 위험을 감소시키는 것인, 방법.
- 청구항 31 또는 32에 있어서, 상기 에페글레나타이드는 임의의 하나 이상의 다른 치료 물질과 병용하여 투여하는 것인, 방법.
- 청구항 58에 있어서, 상기 다른 치료 물질은 혈당강하 약물, 심장보호 약물, 항당뇨병제, 항비만제, 항고지혈증제, 항죽상동맥경화제, 항고혈압제, 항혈소판제, 항혈전제 및 항응고제로부터 선택되는 것인, 방법.
- 청구항 58에 있어서, 상기 다른 치료 물질은 SGLT2(sodium glucose co-transporter 2) 억제제 및 메트포르민 중에서 선택되는 것인, 방법.
- 제2형 당뇨병 환자의 치료에 사용하기 위한 에페글레나타이드의 용도로서,상기 에페글레나타이드는 상기 환자에서 심혈관 질환 또는 신장 기능장애의 발생을 예방하거나, 이의 발생의 위험을 감소시키는 것인, 용도.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023578950A JP2024522844A (ja) | 2021-06-25 | 2022-06-24 | 心血管疾患または腎臓機能障害の発生危険性を低減させるためのエフペグレナチド |
CN202280044671.0A CN117545499A (zh) | 2021-06-25 | 2022-06-24 | 一种用于降低发生心血管疾病或肾功能障碍的风险的艾培格那肽 |
EP22828819.7A EP4360644A1 (en) | 2021-06-25 | 2022-06-24 | Efpeglenatide to reduce risk of developing cardiovascular disease or renal dysfunction |
BR112023027273A BR112023027273A2 (pt) | 2021-06-25 | 2022-06-24 | Composição farmacêutica, método para prevenir o desenvolvimento de doença cardiovascular ou disfunção renal, e, uso de efpeglenatida |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0083100 | 2021-06-25 | ||
KR1020210083100A KR20230000682A (ko) | 2021-06-25 | 2021-06-25 | 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022270972A1 true WO2022270972A1 (ko) | 2022-12-29 |
Family
ID=84544641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/009027 WO2022270972A1 (ko) | 2021-06-25 | 2022-06-24 | 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4360644A1 (ko) |
JP (1) | JP2024522844A (ko) |
KR (1) | KR20230000682A (ko) |
CN (1) | CN117545499A (ko) |
BR (1) | BR112023027273A2 (ko) |
WO (1) | WO2022270972A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008082274A1 (en) | 2007-01-05 | 2008-07-10 | Hanmi Pharmaceutical Co., Ltd. | An insulinotropic complex using an immunoglobulin fragment |
WO2009011544A2 (en) | 2007-07-16 | 2009-01-22 | Hanmi Pharmaceutical Co., Ltd. | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
WO2014017845A2 (en) | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | A liquid formulation of long acting insulinotropic peptide conjugate |
US20210087250A1 (en) * | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
-
2021
- 2021-06-25 KR KR1020210083100A patent/KR20230000682A/ko unknown
-
2022
- 2022-06-24 BR BR112023027273A patent/BR112023027273A2/pt unknown
- 2022-06-24 JP JP2023578950A patent/JP2024522844A/ja active Pending
- 2022-06-24 WO PCT/KR2022/009027 patent/WO2022270972A1/ko active Application Filing
- 2022-06-24 CN CN202280044671.0A patent/CN117545499A/zh active Pending
- 2022-06-24 EP EP22828819.7A patent/EP4360644A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008082274A1 (en) | 2007-01-05 | 2008-07-10 | Hanmi Pharmaceutical Co., Ltd. | An insulinotropic complex using an immunoglobulin fragment |
WO2009011544A2 (en) | 2007-07-16 | 2009-01-22 | Hanmi Pharmaceutical Co., Ltd. | Insulinotropic peptide derivative wherein its n-terminal amino acid is modified |
WO2014017845A2 (en) | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | A liquid formulation of long acting insulinotropic peptide conjugate |
US20210087250A1 (en) * | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
Non-Patent Citations (4)
Title |
---|
DEL PRATO STEFANO, KANG JAHOON, TRAUTMANN MICHAEL E., STEWART JOHN, SORLI CHRISTOPHER H., DERWAHL MICHAEL, SOTO ALFONSO, YOON KUN‐: "Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, GB, vol. 22, no. 7, 1 July 2020 (2020-07-01), GB , pages 1176 - 1186, XP093016648, ISSN: 1462-8902, DOI: 10.1111/dom.14020 * |
GERSTEIN HERTZEL C., BRANCH KELLEY, HEENAN LAURA, DEL PRATO STEFANO, KHURMI NARDEV S., LAM CAROLYN S. P., PRATLEY RICHARD, ROSENST: "cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, GB, vol. 23, no. 2, 1 February 2021 (2021-02-01), GB , pages 318 - 323, XP093016613, ISSN: 1462-8902, DOI: 10.1111/dom.14223 * |
KRISTENSEN SØREN L, RØRTH RASMUS, JHUND PARDEEP S, DOCHERTY KIERAN F, SATTAR NAVEED, PREISS DAVID, KØBER LARS, PETRIE MARK C, MCMU: "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials", THE LANCET / DIABETES & ENDOCRINOLOGY, ELSEVIER, UK, vol. 7, no. 10, 1 October 2019 (2019-10-01), UK , pages 776 - 785, XP009542023, ISSN: 2213-8587, DOI: 10.1016/S2213-8587(19)30249-9 * |
YOON KUN‐HO, KANG JAHOON, KWON SE CHANG, TRAUTMANN MICHAEL E., HOMPESCH MARCUS, STEWART JOHN, SORLI CHRISTOPHER H.: "Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, GB, vol. 22, no. 8, 1 August 2020 (2020-08-01), GB , pages 1292 - 1301, XP093016658, ISSN: 1462-8902, DOI: 10.1111/dom.14032 * |
Also Published As
Publication number | Publication date |
---|---|
KR20230000682A (ko) | 2023-01-03 |
EP4360644A1 (en) | 2024-05-01 |
BR112023027273A2 (pt) | 2024-03-12 |
CN117545499A (zh) | 2024-02-09 |
JP2024522844A (ja) | 2024-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Blonde et al. | Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial | |
Gilbert et al. | GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials | |
Umpierrez et al. | Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) | |
Engel et al. | Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis | |
US6989148B2 (en) | Treatment of diabetes | |
Bonadonna et al. | Novel antidiabetic drugs and cardiovascular risk: Primum non nocere | |
WO2012165915A2 (en) | Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
Del Prato et al. | Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials | |
US20210299129A1 (en) | Cardiosafe Antidiabetic Therapy | |
Verma et al. | Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease | |
Burness et al. | Dulaglutide: a review in type 2 diabetes | |
Aroda et al. | Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes | |
WO2022270972A1 (ko) | 심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드 | |
Wełnicki et al. | The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society | |
Mathieu et al. | Reaction to ketamine: anaphylactoid or anaphylactic? | |
Dhillon | Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis | |
Cai et al. | Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial | |
WO2022245089A1 (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
Dey et al. | The effect of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes | |
Kılıçkap et al. | An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors | |
WO2022132712A1 (en) | Methods of treating diabetes | |
CA1336492C (en) | Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon | |
Dey et al. | The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes | |
Morris | GLP-1 receptor agonists in type 2 diabetes: An underused asset? | |
US20220267402A1 (en) | Long-lasting glp1 analogue drug for type-2 diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22828819 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023578950 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18573370 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280044671.0 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023027273 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2024/000251 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022828819 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022828819 Country of ref document: EP Effective date: 20240125 |
|
ENP | Entry into the national phase |
Ref document number: 112023027273 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231222 |